Alzheimer's disease (AD) is the most common chronic neurodegenerative disease
worldwide. It causes cognitive dysfunction, such as aphasia and agnosia, and mental …

Drug discovery and clinical trial design for dementia have historically been challenging. In
part these challenges have arisen from patient heterogeneity, length of disease course, and …

After identification of lead compound 6, 5-amino-1, 4-oxazine BACE1 inhibitors were
optimized in order to improve potency, brain penetration, and metabolic stability. Insertion of …

Ethnopharmacological relevance Multi-targeted drug therapy has received substantial
attention for the treatment of diseases of multifactorial origin, such as neurodegenerative …

Cardiotoxicity remains a major challenge in drug development, accounting for 45% of
medication withdrawals due to cardiac ischemia and arrhythmogenicity. To overcome the …

This chapter aims to explain the important roles that specific enzymes play in the etiology of
Alzheimer's Disease (AD). Emphasis is placed on enzymes such as beta-secretase 1 …

Over the past historical period, views on Alzheimer's disease therapy have undergone
significant changes. This was facilitated by new research in the framework of studying the …

Because of the intricate nature of the nervous systems, neurological diseases have always
been one of the least studied areas of pathology and medicine. Currently, there is no cure …